GNAS drives gastric cancer progression via pyrimidine metabolic reprogramming and immune-microenvironment remodeling
This work identified GNAS as a key metabolic hub gene, which is consistently upregulated in highly malignant subsets and strongly predictive of poor patient survival, and Targeting the GNAS-mediated metabolic-transcriptional axis exposes a novel therapeutic vulnerability.